Procter & Gamble delivered adjusted earnings per share of $1.88 in its fiscal second quarter, exceeding the consensus forecast of $1.86 by two cents and matching last year’s result. The company generated $22.21 billion in revenue, narrowly trailing consensus estimates by approximately $150 million. Net margin expanded to 19.74%, while return on equity climbed to 32.63%, reflecting disciplined cost control and favorable product mix. Organic sales growth was flat year-over-year, as pricing increases offset a one percent decline in volume.

In response to the quarter’s results, a number of brokerages raised their full-year earnings outlooks. UBS lifted its fiscal 2026 EPS range to $6.83–$7.09, while Deutsche Bank reiterated a Buy rating and increased its target to reflect stronger margin assumptions. Wells Fargo maintained an Overweight rating after narrowing its price target range, and Piper Sandler initiated coverage with a Neutral view, noting resilient cash returns. Collectively, twelve analysts now rate the stock a Buy and nine a Hold, with a consensus EPS forecast of $6.96 for the full year.

Procter & Gamble announced a quarterly dividend of $1.0568 per share, payable February 17 to shareholders of record January 23, representing a 2.8% yield on the current share count and a payout ratio of 61.75%. In the quarter, the company repurchased $2.3 billion of stock, on top of $2.5 billion in dividend payments, returning a total of $4.8 billion to investors. Operating cash flow reached $5.0 billion, with adjusted free cash flow productivity at 88%. The firm’s debt-to-equity ratio remains conservative at 0.46, supporting ongoing returns to shareholders.

Management reaffirmed full-year organic sales growth guidance of in-line to +4%, and core EPS growth of in-line to +4%, translating into a $6.83–$7.09 range. Commodity costs are expected to be neutral for fiscal 2026, with foreign exchange providing a modest tailwind of $200 million after tax, offsetting $400 million in tariff headwinds. Capital expenditures are projected at 4–5% of net sales, and adjusted free cash flow productivity is targeted at 85–90%. The company highlighted ongoing investments in data analytics and digital tools to drive innovation and improve execution across its Beauty, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care segments.